Navigation Links
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Date:10/25/2007

0 mg/day and 40 mg/day. The 80 mg/day dose used in this study is not an approved dose.

Study Findings

The post-hoc pooled analysis is based on results from a randomized controlled trial (RCT) of 84 patients and an open-label study (OLS) of 251 patients, all with euvolemic or hypervolemic hyponatremia.

After infusion of a 20 mg loading dose or placebo, VAPRISOL was given in a continuous 4-day infusion of 40 or 80 mg/d in the RCT and 20 or 40 mg/d in the OLS. Follow-up time after the 4-day treatment included serum [Na+] assessments at day 11 for both groups as well as day 34 for the OLS group only. The primary endpoint of both studies was the change from baseline in serum [Na+] over the entire course of treatment (expressed as the area under the curve, or AUC). Secondary endpoints included: time to reach a greater than or equal to 4 mEq/L increase in serum [Na+]; total time during which patients had a greater than or equal to 4 mEq/L increase in serum [Na+]; change in serum [Na+] at day four; and number of patients who achieved a greater than or equal to 6 mEq/L increase in serum [Na+] or a normal serum [Na+] (greater than or equal to 135 mEq/L) over the course of the study.

Across both studies, patients receiving VAPRISOL showed significant increases in serum [Na+] starting on day one of treatment, with a sustained increase in serum [Na+] one to four weeks after the completion of the studies. In each VAPRISOL dosing group, mean time to a confirmed greater than or equal to 4-mEq/L increase was ~24 hours and the increase was maintained above baseline for most of the treatment period. By day four, VAPRISOL increased serum [Na+] above baseline (mean) from 6.8 to 9.7 mEq/L across the studies. Most VAPRISOL-treated patients achieved a confirmed greater than or equal to 6-mEq/L increase in serum [Na+] or normal serum [Na+] (69 to 88.5 percent in the RCT and 70.3 to 72 percent in the OLS).

In the RCT, VAPRISOL was significantly more effective th
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
(Date:9/1/2014)... (PRWEB) September 01, 2014 The B-cell ... growth across six major markets (the US, France, Italy, ... 2013 to $5.41 billion by 2018. , The competitive ... France, Italy, Germany, Spain and the UK is poised ... Disease management of the four largest B-cell NHL indications, ...
(Date:9/1/2014)... September 2014: Permanent atrial fibrillation (AF) doubles the risk ... in more than 6 000 patients presented at ESC ... findings suggest that a simple clinical assessment of the ... stroke risk. , Ischaemic stroke is the second cause ... million deaths and many more disabled patients each year. ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... September 01, 2014 Ontraport , ... marketers that was developed to automate the small intricacies ... attention of Shane Michaels, prompting an investigative review. ... daily duty of managing all of the small details ... quite overwhelming,” reports Michaels. “That’s why Ontraport has become ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... can lay siege on the victim's disposition and way of ... of coolness can act as an effective pain// reliever. Scientists ... that enable feelings of coolness, and bring immense relief to ... for improved treatment measures for people suffering long-term pain, as ...
... President of the Canadian Medical Association (CMA) said that Canadian ... health of their own children// although in general they rated ... to a survey carried out by Ipsos-Reid, commissioned by the ... kids aged 2-17 are obese/overweight, however only 9% of Canadian ...
... are high during air travel, and not with other forms of ... blood clots can from during any form of travel where the ... has revealed that traveling for more than four hours by air, ... This was substantiated when the research team analyzed 2000 people, who ...
... phobia or fear of needles can be overcome by ... to researchers at the University of New Mexico's// (UNM) ... needles can impact the care a patient receives. ... of needles, whereas some adults avoid the doctor's office ...
... institutions claim to have found that nearly 19% of ... to a direct// result of war. ,Now ... would get the proper treatment necessary. Their fears see ... now mental health treatment from the Department of Veterans ...
... every month for several problems ranging from arthritis to ... enrolled// in Medicare Part D, the new federal prescription-drug ... plan paid for most of their drugs, minus $20 ... coverage stopped. Donna was told by a pharmacist that ...
Cached Medicine News:Health News:American War Veterans Not Receiving Enough Care For PTSD 2Health News:Many American senior citizens fall into the “Doughnut Hole” 2Health News:Many American senior citizens fall into the “Doughnut Hole” 3Health News:Many American senior citizens fall into the “Doughnut Hole” 4
... remove a cast from an arm or leg ... are cut or burned by the cast saw ... to remove any cast with confidence. This innovative, ... and burns from the cast saw and can ...
... or creation of a vascular access, a ... of the utmost importance in many vascular ... those seeking a high-precision tunneling instrument. The ... of twisting or kinking for more accurate ...
... Stretch Vascular Grafts have met the ... procedures. Recognized for exceptional performance and ... of renowned surgeons worldwide. These grafts ... the spread of infection, and ensure ...
... Stretch Vascular Grafts have met the ... procedures. Recognized for exceptional performance and ... of renowned surgeons worldwide. These grafts ... the spread of infection, and ensure ...
Medicine Products: